TIS 0.00% 0.0¢ tissue therapies limited

EMA SAWP meeting, page-7

  1. 85 Posts.
    lightbulb Created with Sketch. 2
    Good points and as you say, transparency is a must.

    Now we need to have a more constructive approach.
    Together
    Let's see ways to build Enterprise Value. This is the most important point at this stage.

    The points reported evidence failures or mistakes.

    Beside the IP transfer, we have to follow  a more oriented market approach to aim a better valuation.

    Any idea?

    I would like to meet and know you personally in Australia in July.
    Is this possible?
    You can use my private email:
    [email protected]
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.